This Article Full Text Full Text (PDF) eLetters: Submit a response to this article Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article link to a friend Similar articles in this journal Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Zhu, A. X. Search for Related Content PubMed Articles by Zhu, A. X.

Hepatobiliary

Systemic Therapy of Advanced Hepatocellular Carcinoma: How Hopeful Should We Be?

Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts, USA

Key Words. Hepatocellular carcinoma • Molecularly targeted agents • Systemic therapy

Correspondence: Andrew X. Zhu, M.D., Ph.D., Tucker Gosnell Center for Gastrointestinal Cancers, Massachusetts General Hospital Cancer Center, 100 Blossom Street, Cox 640, Boston, Massachusetts 02114, USA. Telephone: 617-724-0786; Fax: 617-724-3166; e-mail: azhu{at}partners.org

Worldwide, hepatocellular carcinoma (HCC) is the fifth most common cancer and the third most common cause of cancer-related death. In the U.S., 18,510 new cancers of the liver and intrahepatic bile duct are expected in 2006, with an estimated 16,200 deaths. The incidence rates for HCC in the U.S. continued to rise steadily through 1998 and doubled during the period 1975–1995. Unresectable or metastatic HCC carries a poor prognosis, and systemic therapy with cytotoxic agents provides marginal benefit. A majority of HCC patients (>80%) presents with advanced or unresectable disease. Even for those with resected disease, the recurrence rate can be as high as 50% at 2 years. Because of the poor track record of systemic therapy in HCC, there has been a sense of nihilism for this disease in the oncology community for decades. However, with the arrival of newly developed molecularly targeted agents and the success of some of these agents in other traditionally challenging cancers, like renal cell carcinoma, there has recently been renewed interest in developing systemic therapy for HCC. This review attempts to concisely summarize the historical perspective and the current status of systemic therapy development in HCC.

This article has been cited by other articles:

				X.-L. Xu, B.-C. Xing, H.-B. Han, W. Zhao, M.-H. Hu, Z.-L. Xu, J.-Y. Li, Y. Xie, J. Gu, Y. Wang, et al. The properties of tumor-initiating cells from a hepatocellular carcinoma patient's primary and recurrent tumor Carcinogenesis, February 1, 2010; 31(2): 167 - 174. [Abstract] [Full Text] [PDF]

				A. X. Zhu, D. V. Sahani, D. G. Duda, E. di Tomaso, M. Ancukiewicz, O. A. Catalano, V. Sindhwani, L. S. Blaszkowsky, S. S. Yoon, J. Lahdenranta, et al. Efficacy, Safety, and Potential Biomarkers of Sunitinib Monotherapy in Advanced Hepatocellular Carcinoma: A Phase II Study J. Clin. Oncol., June 20, 2009; 27(18): 3027 - 3035. [Abstract] [Full Text] [PDF]

				C. Hu, H. Li, J. Li, Z. Zhu, S. Yin, X. Hao, M. Yao, S. Zheng, and J. Gu Analysis of ABCG2 expression and side population identifies intrinsic drug efflux in the HCC cell line MHCC-97L and its modulation by Akt signaling Carcinogenesis, December 1, 2008; 29(12): 2289 - 2297. [Abstract] [Full Text] [PDF]

				H. Huynh, V. C. Ngo, J. Fargnoli, M. Ayers, K. C. Soo, H. N. Koong, C. H. Thng, H. S. Ong, A. Chung, P. Chow, et al. Brivanib Alaninate, a Dual Inhibitor of Vascular Endothelial Growth Factor Receptor and Fibroblast Growth Factor Receptor Tyrosine Kinases, Induces Growth Inhibition in Mouse Models of Human Hepatocellular Carcinoma Clin. Cancer Res., October 1, 2008; 14(19): 6146 - 6153. [Abstract] [Full Text] [PDF]

				B. C. Fuchs, T. Fujii, J. D. Dorfman, J. M. Goodwin, A. X. Zhu, M. Lanuti, and K. K. Tanabe Epithelial-to-Mesenchymal Transition and Integrin-Linked Kinase Mediate Sensitivity to Epidermal Growth Factor Receptor Inhibition in Human Hepatoma Cells Cancer Res., April 1, 2008; 68(7): 2391 - 2399. [Abstract] [Full Text] [PDF]

				Y.-F. Wu, S.-L. Fu, C.-H. Kao, C.-W. Yang, C.-H. Lin, M.-T. Hsu, and T.-F. Tsai Chemopreventive Effect of Silymarin on Liver Pathology in HBV X Protein Transgenic Mice Cancer Res., March 15, 2008; 68(6): 2033 - 2042. [Abstract] [Full Text] [PDF]

				V. de Villa and C. M. Lo Liver Transplantation for Hepatocellular Carcinoma in Asia Oncologist, November 1, 2007; 12(11): 1321 - 1331. [Abstract] [Full Text] [PDF]

				H. Huynh, P. K.H. Chow, and K.-C. Soo AZD6244 and doxorubicin induce growth suppression and apoptosis in mouse models of hepatocellular carcinoma Mol. Cancer Ther., September 1, 2007; 6(9): 2468 - 2476. [Abstract] [Full Text] [PDF]

				V. K.-S. Kho and W.-C. Chen Hepatocellular Carcinoma Presenting As Radiculopathy J. Clin. Oncol., May 1, 2007; 25(13): 1805 - 1806. [Full Text] [PDF]